Infliximab in the treatment of rheumatoid arthritis

Aging Health

Volumn 2, Issue 1, 2006, Pages 19-33

  Augustsson, Jenny ^a   Jonsdottir, Thorunn ^a   Klareskog, Lars ^a   van Vollenhoven, Ronald F ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Arthritis; Autoimmune; Elderly; Inflammation; Infliximab; Rheumatoid; Tumor necrosis factor

Indexed keywords

ABATACEPT; ADALIMUMAB; ADRENALIN; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; AZATHIOPRINE; CARDIOLIPIN ANTIBODY; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABDOMINAL PAIN; ABSCESS; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ARTICLE; ARTIFICIAL VENTILATION; BACKACHE; BACTERIAL INFECTION; BLOOD TOXICITY; BRONCHITIS; CANDIDIASIS; CELLULITIS; CLINICAL FEATURE; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; COUGHING; DEMYELINATING DISEASE; DEPRESSION; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INFUSION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; FATIGUE; FEVER; FLUSHING; HEADACHE; HISTOPLASMOSIS; HUMAN; HYPERTENSION; IMMUNOGENICITY; IMMUNOTOXICITY; LEUKEMIA; LISTERIOSIS; LOW DRUG DOSE; LYMPHOMA; META ANALYSIS; MULTIPLE SCLEROSIS; MYCOBACTERIOSIS; MYCOBACTERIUM TUBERCULOSIS; MYCOSIS; NAUSEA; NONHUMAN; OPPORTUNISTIC INFECTION; PAIN; PATHOGENESIS; PERIPHERAL EDEMA; PHARYNGITIS; PHYSICAL DISABILITY; PNEUMOCYSTOSIS; PNEUMONIA; POSTMARKETING SURVEILLANCE; PROTEIN FUNCTION; PRURITUS; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; RHINITIS; SEPSIS; SIDE EFFECT; SINUSITIS; SKIN ULCER; STOMATITIS; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC VASCULITIS; THORAX PAIN; TREATMENT OUTCOME; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; VOMITING;

EID: 33646596551     PISSN: 1745509X     EISSN: 17455103     Source Type: Journal    
DOI: 10.2217/1745509X.2.1.19     Document Type: Article

References (91)

1. Firestein GS: Estiology and pathogenesis of rheumatoid arthritis. In: Kelley's Textbook of Rheumatology (Volume 2, 7th Edition). Harris ED (Ed). Elsevier Science, USA, 996-1042 (2005).
2. Fex E, Jonsson K, Johnsson U, Eberhardt K: Development of radiographic damage during the first 5-6 yr of rheumatoid arthritis: a prospective follow-up study of a Swedish cohort. Br. J. Rheumatol. 35, 1106-1115 (1996).
3. Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T: Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J. Rheumatol. 15, 585-591 (1989).
4. Mottonen TT: Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis. Ann. Rheum. Dis. 47, 648-653 (1988).
5. Harris ED: Clinical features of rheumatoid arthritis. In: Kelley's Textbook of Rheumatology (Volume 2, 7th Edition). Harris ED (Ed.) Elsevier Science, USA, 1043-1078 (2005).
6. Watson DJ, Rhodes T. Guess HA: All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J. Rheumatol. 30, 1196-1202 (2003).
7. Kobelt G, Eberhardt K, Jönsson L, Jönsson B: Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum. 42, 347-356 (1999).
8. Choy EH, Panayi GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344, 907-916 (2001).
9. Feldman M, Maini RN: The role of cytokines in the pathogenesis of rheumatoid arthritis. Rheumatalogy 38(Suppl. 2), 3-7 (1999).
10. Smith JB, Haynes MK: Rheumatoid arthritis: a molecular understanding. Ann. Intern. Med. 136, 908-922 (2002).
11. Mottonen TT. Hannonen P, Leirisalo-Repo M et al.: Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet 353, 1568-1573 (1999).
12. Boers M, Verheoeven AC, Markusse HM et al.: Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350, 309-318 (1997).
13. Lard LR, Boers M, Verhoeven A: Early and aggressive treatment of rheumatoid arthritis atients affects the association of hla class ii antigen agents with progression of joint damage. Arthritis Rheum. 46 (4) 899-905 (2002).
14. Landewe RB, Geusens P, van der Heijde D, Boers M, van der Linden S, Garnero P: Arthritis instantaneously causes collagen type-I and type-II degradation in patients with early rheumatoid arthritis. Ann. Rheum. Dis. 65(1), 40-44 (2005).
15. Pincus T, Sokka T, Kautiainen H: Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum. 52(4), 1009-1019 (2005).
16. van Vollenhoven RF, Klareskog L: The treatment of rheumatoid arthritis: getting better all the time? Arthritis Rheum. 52 (4), 991-994 (2005).
17. Wolfe F, Hawley DJ, Cathey MA: Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J. Rheumatol. 17, 994-1002 (1990).
18. Remicadeo® (infliximab) current prescribing information.
19. Enbrel® (etanercept) current prescribing information.
20. Humira® (adalimumab) current prescribing information.
21. Edwards JC, Szczepanski L, Szechinski J et al: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350, 2572-2581 (2004).
22. Kremer JM, Dougados M, Emery P et al.: Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 52(8), 2263-2271 (2005).
23. Nishimoto N, Yoshizaki K, Miyasaka N et al.: Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 50(6), 1761-1769 (2004).
24. Baslund B, Tvede N, Danneskiold-Samsoe B et al.: Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum. 52 (9). 2686-2692 (2005).
25. Smeets RL, van de Loo FA, Arntz OJ, Bennink MB, Joosten LA, van den Berg WB: Adenoviral delivery of IL-18 binding protein C ameliorates collagen-induced arthritis in mice. Gene Ther. 10, 1004-1011 (2003).
26. Remicade® package insert. Centocor Inc., PA, USA.
27. Knight DM, Trinh H, Le J et al: Construction and initial characterization of a mouse-human chimeric antiTNF antibody. Mol. Immunol. 30(16), 1443-1453 (1993).
28. Siegel SA, Shealy DJ, Nakada MT et al.: The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 7(1), 15-25 (1995).
29. Van Dullemen HM, Van Deventer SJH, Hommes DW et al.: Treatment of Crohn's disease with antitumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109(1), 129-135 (1995).
30. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J: Chimeric antiTNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7(3), 251-259 (1995).
31. Maini RN, Breedveld FC, Kalden JR et al.: Therapeutic efficacy of multiple intravenous infusions of antitumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41, 1552-1563 (1998).
32. Felson DT Anderson JJ, Boers M et al.: The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 36(6), 729-740 (1993).
33. Felson DT Anderson JJ, Boers M et al.: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38(6), 727-735 (1995).
34. van der Heijde DM, van't Hof M, van Riel PL, van de Putte LB: Development of a disease activity score based on judgment in clinical practice by rheumatologists. J. Rheumatol. 20(3), 579-581 (1993).
35. van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 39(1), 34-40 (1996).
36. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38(1), 44-48 (1995).
37. van der Heijde DM, van Leeuwen MA, van Riel PL et al.: Biannual radiographic assessment of hands and feet in a three-year prospective follow-up of patients with early RA. Arthritis Rheum. 35, 26-34 (1992).
38. Fries J, Spitz P, Kraines R, Holman H: Measurement of patient outcome in arthritis. Arthritis Rheum. 23, 137-145 (1980).
39. Kobelt G, Jönsson L, Lindgren P, Young A, Eberhardt K: Modeling the progression of rheumatoid arthritis. A two-country-model to estimate cost and consequences of RA. Arthritis Rheum. 46, 2310-2319 (2002).
40. Hurst N, Kind P, Ruta D, Hunter M, Stubbings A: Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br. J. Rheumatol. 36, 551-559 (1997).
41. Elliott MJ, Maini RN, Feldmann M et al.: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor-α. Arthritis Rheum. 36, 1681-1690 (1993).
42. Elliott MJ, Maini RN, Feldmann M et al.: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344, 1105-1110 (1994).
43. Kavanaugh A, St Clair EW, McCune WJ et al.: Chimeric antitumor necrosis factor-α monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J. Rheumatol. 27, 841-850 (2000).
44. Maini R, St Clair EW, Breedveld F et al.: Infliximab (chimeric antitumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. Lancet 354, 1932-1939 (1999).
45. Lipsky PE, van der Heijde DM, St Clair EW et al.: Inffiximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. 343, 1594-1602 (2000).
46. Maini RN, Breedvled FC, Kaiden JR et al.: Sustained improvement over two years in physical function, structural damage, and signs and symptom among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 50(4), 1051-1065 (2004).
47. St Clair EW, van der Heijde DM, Smolen JS et al.: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. A randomized controlled trial. Arthritis Rheum. 50(11), 3432-3443 (2004).
48. Breedveld FC, Emery P. Keystone E et al.: Infliximab in active early rheumatoid arthritis. Ann. Rheum. Dis. 63, 149-155 (2004).
49. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 52(11), 3381-3390 (2005).
50. Quinn MA, Conaghan PG, O'Connor PJ et al.: Very early treatment with infliximab in addition to methotrexate in early, poorprognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 52(1), 27-35 (2005).
51. Kiely PD, Johnson DM: Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open label study. Rheumatology 4l, 631-637 (2002).
52. Hansen KE, Cush J, Singhal A et al.: The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis. Arthritis Rheum. 51(2), 228-232 (2004).
53. Flendrie M, Creemers MC, Welsing PM, van Riel PL: The influence of previous and concomitant leflunomide in the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study. Rheumatology 44, 472-478 (2005).
54. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH: Comparison of the efficacy of the tumour necrosis factor ot blocking agents adalimumab, etanercept, and infliximab when added to MTX in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 62(Suppl. II), ii13-ii16 (2003).
55. van Vollenhoven RF, Klareskog L: Clinical response to tumor necrosis factor α antagonists do not show a bimodal distribution. Arthritis Rheum. 48(6), 1500-1503 (2003).
56. Geborek P, Crnkic M, Petersson IF, Saxne T: Etanercept, infliximab and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow-up programme in southern Sweden. Ann. Rheum. Dis. 61, 793-798 (2002).
57. van Vollenhoven R, Harju A, Brannemark S, Klareskog L: Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann. Rheum. Dis. 62(12), 1195-1198 (2003).
58. Hansen KE, Hildebrand JP, Genovese MC et al.: The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J. Rheumatol. 31(6), 1098-1102 (2004).
59. Chevillotte-Maillard H, Ornetti P, Mistrih R et al.: Survival and safety of treatment with infliximab in the elderly population. Rheumatology 44(5), 695-696 (2005).
60. Jonsdottir T, Forslid J, van Vollenhoven A et al.: Treatment with tumour necrosis factor α antagonists in patients with rheumatoid arthritis induces anticardioltpin antibodies. Ann. Rheum. Dis. 63, 1075-1078 (2004).
61. Flendrie M, Creemers MC, Welsing PM, den Broeder AA. van Riel PL: Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann. Rheum. Dis. 62(Suppl. II), ii30-ii33 (2003).
62. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero, MD, BIOBADASER Group: Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk. Arthritis Rheum. 48(8), 2122-2127 (2003).
63. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V et al.: Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 52(6), 1766-1772 (2005).
64. Silman AJ, Hyrich K, Symmons DP, Watson K, Control Centre Consortium B: Baseline comorbidity levels in biologic and standard dmard treated patients with rheumatoid arthritis: results from a national patient register. Ann. Rheum. Dis. (2005) (Epub ahead of print).
65. Franklin J, Lunt M, Bunn D, Symmons DP, Silman AJ: Incidence of lymphoma in a large primary-care derived cohort of inflammatory polyarthritis. Ann. Rheum. Dis. (2005) (Epub ahead of print).
66. Ehlers S: Role of tumour necrosis factor (TNF) in host defenece against tuberculosis: Implications for immunotherapies targeting TNF. Ann. Rheum. Dis. 62 (Suppl. II), ii37-ii42 (2003).
67. Keane J, Gershon S, Wide RP et al.: Tuberculosis associated with infliximab a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med 345, 1098-1104 (2001).
68. British Thoracic Society Standards of Care Committee: BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start antiTNF-α treatment. Thorax 60, 800-805 (2005).
69. Askling J, Fored M, Brandt L et al.: Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 52(7), 1986-1992 (2005).
70. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM: Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 46(12). 3151-3158 (2002).
71. Geborek P, Bladstrom A, Turesson C et al.: Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann. Rheum. Dis. 64(5), 699-703 (2005).
72. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH: Rheumatoid arthritis and cancer risk. Eur. J. Cancer 32A(10), 1753-1757 (1996).
73. Ekstrom K, Hjalgrim H, Brandt L et al.: Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum. 48, 963-970 (2003).
74. Baecklund E, Ekbom A, Sparen P Feltelius N, Klareskog L: Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. Br. Med. J. 317, 180-181 (1998).
75. Askling J. Fored M, Baecklund E et al.: Hematopoietic malignancies in rheumatoid arthritis. Lymphoma risk and characteristics following TNF-antagonists. Ann. Rheum. Dis. 64(10), 1414-1420 (2005).
76. Cush JJ: Cytokine inhibitors. In: Rheumatology (3rd Edition). Hochberg MC, Silman AJ, Smolen J, Weinblatt ME, Weissman (Eds). Mosby, Edinburgh, UK, 461-484 (2003).
77. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, AntiTNF therapy against congestive heart failure investigators: Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the AntiTNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107(25), 3133-3140 (2003).
78. Mann DL, McMurray JJ, Packer M et al.: Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109(13), 1594-1602 (2004).
79. Wolfe F, Michaud K: Heart failure in rheumatoid arthritis: rates predictors, and the effect of antitumour necrosis factor therapy. Am. J. Med. 116(5), 305-311 (2004).
80. Khanna D, McMahon M, Furst DE: Antitumour necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here? Arthritis Rheum. 50, 1040-1050 (2004).
81. Jacobsson LT, Toresson C, Gulfe A et al.: Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J. Rheumatol. 32(7), 1213-1218 (2005).
82. Solomon DH, Karlson EW, Rimm EB et al.: Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107, 1303-1307 (2003).
83. Mohan N, Edwards ET, Cupps TR et al.: Demyelination occurring during antitumor necrosis factor-α therapy for inflammatory arthritides. Arthritis Rheum. 44, 2862-2869 (2001).
84. Robinson WH, Genovese MC, Moreland LW: Demyelinating and neurologic events reported in association with tumor necrosis factor-α antagonism. By what mechanism could tumor necrosis factor-α antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis. Arthritis Rheum. 44, 1977-1983 (2001).
85. Noonan CW Kathman SJ, White MC: Prevalence estimates of MS in the United States and evidence of an increasing trend for women. Neurology 58, 136-138 (2002).
86. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG: Multiple sclerosis. N. Engl. J. Med. 343, 938-952 (2000).
87. Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti, Montecucco C: Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res. Ther. 6(3), R264-R272 (2004).
88. Augustsson J, Ernestam S, Eksborg S, Gullstrom E, van Vollenhoven RF: Daily low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reactions to infliximab. Arthritis Rheum. 52(9), S338 (2005).
89. Crandall WV, Mackner LM: Infusion reactions to infliximab in children and adolescents: frequency, outcome and predictive model. Aliment. Pharmacol. Ther. 17(1), 75-84 (2003).
90. Kugathasan S. Levy MB, Saelan K et al.: Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am. J. Gastroenterol. 97(6), 1408-1414 (2002).
91. Remicade Medical Information Center, Centocor Inc., PA, USA.